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The molecular mechanism of the anti-adipogenic effect of evodiamine (which has several capsaicin-
like pharmacological actions) was investigated. The evodiamine effect was not blocked by the spe-
ciﬁc TRPV1 antagonist capsazepine in 3T3-L1 preadipocytes, whereas its effect was greatly curtailed
by inhibitors of protein kinase C (PKC) and epidermal growth factor receptor (EGFR). Signal analyses
showed that evodiamine stimulated the phosphorylation of EGFR, PKCa, and ERK, all of which were
reduced by an EGFR inhibitor. Silencing experiments of EGFR mRNA supported the involvement of
these signaling molecules in the inhibitory effect of evodiamine. An unidentiﬁed mechanism
whereby evodiamine inhibits adipogenesis via the EGFR–PKCa–ERK signaling pathway was
revealed.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Adipocytes are the major cellular component in adipose tissues
and have important roles in obesity, insulin resistance, and diabe-
tes mellitus. Because the progress of these diseases is intimately
related to adipocyte hypertrophy and the recruitment of new adi-
pocytes from preadipocytes, manipulation of adipogenesis may
lead to a promising strategy to reduce the incidence of obesity
and diabetes mellitus [1]. The discovery of anti-adipogenic com-
pounds and understanding of their mode of action would contrib-
ute to the development of new dietary interventions and/or clinical
therapies against obesity and diabetes mellitus.
Evodiamine is a major alkaloidal compound extracted from the
fruit of Evodia fructus (Evodia rutaecarpa Benth., Rutaceae), which
has been used for many years as a traditional Chinese herbal
medicine for the treatment of pain, vomiting, and pyresis. Studies
demonstrated that evodiamine exhibited anti-tumor and anti-
inﬂammatory bioactivities [2,3]. These activities are similar to
those of capsaicin and are blocked competitively by capsazepine,chemical Societies. Published by E
ptor; ERK/MAPK, extracellu-
se; MEK, MAPK kinase; PKC,
t receptor potential
mashita).
nd Hepatology, Iwate Medicala speciﬁc antagonist of the capsaicin receptor/transient receptor
potential (TRP) V1 channel [4–6]. Evodiamine is therefore thought
to act as an agonist for TRPV1. TRP channels are non-selective
cation channels found in many animals and are implicated in
diverse cellular functions, including pain sensation, temperature,
osmolality and taste sensation [7]. Kobayashi et al. reported a
capsaicin-like anti-obese activity of evodiamine, which could be
due to serial stimulation of the sympathetic nervous system and
uncoupling protein-1 thermogenesis in brown adipose tissue
(BAT) [8]. Uncoupling protein-1 allows fuel energy to be burned
as heat.
We recently demonstrated that evodiamine improves diet-in-
duced obesity in an uncoupling protein-1-independent manner
[9]. In that report, we revealed that evodiamine (but not capsaicin)
increased phosphorylation of extracellular signal-regulated kinase/
mitogen-activated protein kinases (ERK/MAPK), reduced the
expression of transcription factors such as peroxisome prolifera-
tor-activated receptor-c, and strongly inhibited adipocyte differen-
tiation. The identity of the target of evodiamine and how the signal
is transduced to ERK activation, leading to inhibition of adipogen-
esis, is not known.
In the present study, we explored the anti-adipogenic mecha-
nism of evodiamine, in which evodiamine stimulates protein
kinase C alpha (PKCa) via phosphorylation of the epidermal
growth factor receptor (EGFR), leading to ERK activation. This is
the ﬁrst report that clearly shows a novel inhibitory mechanism
of evodiamine distinct from that of capsaicin on adipogenesis.lsevier B.V. All rights reserved.
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2.1. Cell culture
3T3-L1 preadipocytes, which are mouse embryonic ﬁbroblasts
capable of differentiating into adipocytes, were grown in Dul-
becco’s modiﬁed Eagle’s medium (DMEM; Invitrogen, Grand Is-
land, NY, USA) containing 10% calf serum (CS; ICN Biomedicals,
Aurora, OH, USA). Adipocyte differentiation was carried out as de-
scribed [10]. Brieﬂy, 2 days after conﬂuence, the medium was
changed to DMEM containing 10% fetal bovine serum (ICN),
10 lg/mL insulin, 1 lM dexamethasone, and 0.5 mM 3-isobutyl-
1-methylxanthine. Dexamethasone and 3-isobutyl-1-methylxan-
thine were withdrawn after 2 days of exposure, and insulin
withdrawn after 4 days. We induced 2-day post-conﬂuent preadi-
pocytes to differentiate in the presence of evodiamine (Kishida
Chemicals, Osaka, Japan) or capsaicin (Wako Pure Chemicals, Osa-
ka, Japan) for 4 days and then in its absence for 6 days. Capsazepine
(Tocris Bioscience, Bristol, UK), ruthenium red (Sigma–Aldrich, St.
Louis, MO, USA), PD98059 (Cell Signaling Technology, Danvers,
MA, USA), AG1478 and chelerythrine chloride (Calbiochem, La Jol-
la, CA, USA) were added to the medium together with evodiamine
as required. After 10 days of differentiation, cells were stained with
Oil Red O (Muto Pure Chemicals, Tokyo, Japan).
2.2. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was prepared from tissues and cultured cells with
TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s protocol. After DNase treatment of the total RNA fraction,
1 lg of the RNA sample was reverse transcribed to single-stranded
cDNA using M-MLV reverse transcriptase (Gibco BRL, Gaithersburg,
MD, USA). Detection of TRPV genes was done using cDNA tem-
plates and PCR. The primer sequences used for gene ampliﬁcation
were: TRPV1, ATGGAACAACGGGCTAGCTT and TTGTGCAGATTGAG-
CATGGC; TRPV2, CTACACCTTGGCTTCAGCCT and GTGGAGCCT-
TCTGTGTATGC; TRPV3, GTCTCCTCAGGATGATGTGA and TCAGGGT-
GATGTTGTAGAAG; TRPV4, AGTGGTGGTACCCCTGGATA and AATG-
TAGGTGGGAGCGAAGG; b-actin, AAGTACCCCATTGAACACGG
and CTCCGGAGTCCATCACAATG (forward and reverse primer,
respectively).  MDI                    B
0
A   
Evo+PKCiEvo 
Fig. 1. PKC is involved in the inhibitory effect of evodimine on adipogenesis and2.3. Western blot analysis
Total cell lysates were prepared and analyzed as described [9].
Brieﬂy, the proteins of cell lysates were separated by 4–20% so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) and electrotransferred onto a polyvinylidene diﬂuoride
membrane. Immunoblotting and immunoprecipitation were done
using cell lysates (30 lg and 500 lg, respectively) and speciﬁc anti-
bodies against phospho-tyrosine 4G10 and EGFR (Upstate, Char-
lottesville, VA, USA), b-tubulin (Santa Cruz Biotechnology, Santa
Cruz, USA), p44/42 MAPK, phospho-p44/42 MAPK (Thr202/
Tyr204), MAPK kinase (MEK)1/2, Phospho-MEK1/2 (Ser217/221),
PKCa, Phospho-PKCa/b (Thr638/641), and phospholipase Cc1
(PLCc1, Cell Signaling Technology, Beverly, MA, USA). The immu-
noreactive bands were visualized with an enhanced chemilumi-
nescence reagent (Amersham Biosciences, Amersham, UK).regulation of ERK activation. (A) Effect of chelerythrine chloride (PKC inhibitor
(PKCi)) on ERK phosphorylation. Two-day post-conﬂuent 3T3-L1 preadipocytes
were serum-deprived for 4 h and treated with 20 lM evodiamine (Evo) or an equal
volume of dimethylsulfoxide control (Cont) for 10 min. The PKCi was added at
different concentrations 1 h before evodiamine addition. Lysates were analyzed for
ERK phosphorylation. Data are expressed as the mean ± S.E. (n = 3). (B) Effect of PKCi
on adipogenesis. Cells were cultured in the differentiation medium with 1 lM Evo
in the absence or presence of 10 lM PKCi. Lipid accumulation in cells was evaluated
by Oil Red O staining. Data are representative of three independent experiments.2.4. siRNA transfection
siRNA oligos and control for knockdown of endogenous
EGFR protein were prepared by using the siRNA SMARTpoolTM
EGFR (EGFR siRNA/siABTM assay kit, Dharmacon, Incorporated,
Lafayette, CO, USA). siRNAs were transfected into cells using Lipo-fectAMINE 2000 (Invitrogen) according to manufacturer’s
instructions.
3. Results and discussion
To study the upstream effectors of the ERK signal stimulated by
evodiamine, we initially examined if PKC is involved in the inhib-
itory effect of evodiamine on adipocyte differentiation because
PKC has been implicated in the proliferation, differentiation and
transformation of cells [11]. With respect to adipogenesis regula-
tion, PKCc and PKCe are required to promote adipogenic commit-
ment [12,13], whereas PKCa is highly expressed in preadipocytes
but this expression decreases upon adipocyte differentiation [14].
ERK phosphorylation by evodiamine stimulation was blocked com-
pletely when chelerythrine chloride, an effective inhibitor of PKC
[15], was added to the culture of 3T3-L1 preadipocytes (Fig. 1A).
Treatment of the PKC inhibitor during preadipocyte differentiation
inhibited the evodiamine effect, and stimulated adipogenesis sim-
ilar to that observed in the control culture (Fig. 1B). These results
suggested that evodiamine stimulated ERK phosphorylation and
inhibited adipocyte differentiation via PKC activation.
We next investigated the target molecules of evodiamine,
which leads to activation of PKC and ERK in 3T3-L1 preadipocytes.
The predicted candidate was TRPV1 because evodiamine has cap-
T. Wang et al. / FEBS Letters 583 (2009) 3655–3659 3657saicin-like bioactivities [4–6]. Zhang et al. recently reported that
TRPV1 was abundantly expressed in 3T3-L1 preadipocytes and that
capsaicin inhibited its adipogenesis [16]. We failed to detect the
transcript of TRPV1 mRNA as well as TRPV3 mRNA in 3T3-L1 pre-
adipocytes, although very faint signals of these genes were ob-
served in differentiated adipocytes (Fig. 2A). This observation is
consistent with a report by Motter and Ahern stating that capsaicin
failed to evoke Ca2+ responses in 3T3-L1 preadipocytes [17]. Gene
expression of TRPV2 and TRPV4 mRNAs was observed in preadipo-
cytes and adipocytes, and expression of TRPV4 mRNA was much
higher than that of TRPV2 mRNA, particularly in preadipocytes.
Transcripts of the four TRPV genes were detected in adipose tis-
sues, which contain various cell types. Likewise, we could not de-
tect any effects of capsaicin on ERK phosphorylation nor
adipogenesis in 3T3-L1 cells (Fig. 2B and C and in our previous
study [9]). We do not know the reason for the differences in TRPV1
expression and the effects of capsaicin in 3T3-L1 preadipocytes ob-
served in our study and in Zhang’s study. Nevertheless, our results
strongly suggested that evodiamine stimulates adipogenesis
through an unknown target that is not TRPV1.
We detected a high mRNA level of TRPV4 (which shares about
40% amino-acid homology with TRPV1), so we examined the pos-
sible involvement of TRPV4 in adipocyte differentiation as the tar-
get of evodiamine. Ruthenium red (an inhibitor of TRP channels
including TRPV4) and capsazepine (TRPV1 antagonist) did not pre-
vent the evodiamine effects on ERK phosphorylation and adipogen-
esis in 3T3-L1 preadipocytes (Fig. 2B and C). Primary preadipocytes
derived from the white adipose tissues of TRPV4-deﬁcient mice
differentiated normally into mature adipocytes and evodiamine in-
creased ERK phosphorylation in the cells and blocked their differ-
entiation (Wang, T., Unpublished observation). These resultsPA   A   BAT  WAT
TRPV1
β-actin
TRPV4
TRPV3
TRPV2
3T3-L1
A
B
C
Cont                            
Evo
CPZ-  
Fig. 2. TRPV1 and TRPV4 are not involved in the evodiamine effects on ERK phosphoryla
tissues. RT-PCR using 3T3-L1 preadipocytes (PA) and mature adipocytes (A), brown adipos
(B) Effects of capsaicin (Cap), capsazepine (CPZ) and/or ruthenium red (RR) on ad
differentiation medium with 1 lM evodiamine (Evo) or Cap in the absence or presence o
Data are representative of three independent experiments. (C) Effect of PD98059 (PD) or
or an equal volume of dimethylsulfoxide control (Cont) for 1 h using the same protocol a
are expressed as the mean ± S.E. (n = 3).strongly suggested that TRPV4 is not a target of evodiamine to in-
duce activation of the ERK signaling pathway.
We investigated the receptor tyrosine kinase EGFR as another
candidate of the evodiamine receptor because EGFR signaling has
been reported to have a role in adipogenesis regulation [18]. Inhi-
bition of adipocyte differentiation by evodiamine was recovered by
co-treatment with an EGFR inhibitor, suggesting involvement of
the EGFR in the evodiamine effect (Fig. 3A). The signal analysis re-
vealed that evodiamine stimulated the tyrosine phosphorylation of
EGFR in 3T3-L1 preadipocytes, and that its phosphorylation was
blocked completely by addition of an EGFR inhibitor (Fig. 3B). In
parallel with EGFR phosphorylation, PKCa/b was signiﬁcantly
phosphorylated: it was reduced by the EGFR inhibitor. PKCa is
the most abundant classical PKC isoform and PKCb is not expressed
at the preadipocyte stage [13], so the PKC signal appeared to be
that of PKCa. There were no changes in the phosphorylation levels
of the PKC isoforms PKCd, PKCh, and PKC1/k, in evodiamine-stimu-
lated 3T3-L1 preadipocytes (data not shown); however, the
involvement of PKCc and PKCe in the evodiamine effect remains
to be addressed. Increased phosphorylation of MEK and ERK was
observed after evodiamine stimulation in 3T3-L1 preadipocytes,
whereas their phosphorylation levels were reduced by an EGFR
inhibitor. These results suggested that an EGFR–PKCa–ERK signal
cascade was stimulated by evodiamine in 3T3-L1 preadipocytes.
We conducted a gene-knockdown experiment using siRNA for
EGFR to conﬁrm the involvement of the EGFR–PKCa–ERK signal
pathway in the inhibitory effect of evodiamine on adipogenesis.
The siRNA silenced about 50% of EGFR protein in 3T3-L1 preadipo-
cytes (which differentiated into addipocytes even under evodi-
amine stimulation) whereas non-coding RNA did not prevent the
evodiamine effects (Fig. 4A and B). PLC has a signiﬁcant role inERK1/2
p-ERK1/2
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Fig. 3. Evodiamine inhibits adipogenesis through the EGFR signaling passway. (A)
Effect of AG1478 (EGFR inhibitor (EGFRi)) on adipogenesis. Two-day post-conﬂuent
3T3-L1 preadipocytes were cultured in the differentiation medium with 1 lM
evodiamine (Evo) in the absence or presence of 5 lM EGFRi. Lipid accumulation in
cells was evaluated by Oil Red O staining. Data are representative of three
independent experiments. (B) Time-course of phosphorylation of EGFR, PKCa/b,
MEK, and ERK by evodiamine. Cells were serum-deprived for 4 h and then treated
with 50 lM evodiamine for the indicated time together with or without 1-h
pretreatment with 5 lM EGFRi. Immunoprecipitation (IP) and immunoblot (IB)
analyses were done using cell lysates and antibodies speciﬁc for each molecule as
described in Section 2. Data are expressed as the mean ± S.E. (n = 3).
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Fig. 4. Downregulation of EGFR induced by siRNA reduces evodiamine-induced ERK
activation and its anti-adipogenic effect. (A) Effect of EGFR siRNA on the expression
of EGFR protein. 3T3-L1 preadipocytes were transfected with EGFR siRNA or non-
coding RNA (ncRNA). Three days after transfection, cells were harvested and
analyzed for EGFR expression by western blotting. EGFR level was normalized by b-
tubulin level. Data are expressed as the mean ± S.E. (n = 3). (B) Effect of EGFR siRNA
on the anti-adipogenic effect of evodiamine (Evo). Transfected or non-transfected
cells were cultured in the differentiation medium with 1 lM Evo and lipid
accumulation evaluated by Oil Red O staining. Data are representatives of three
independent experiments. (C) Phosphorylation of PLCc1, PKCa/b, and ERK in Evo-
stimulated cells with or without siRNA transfection. Cells were serum-deprived for
4 h and then treated with 50 lM Evo or an equal volume of dimethylsulfoxide
control (Cont) for 1 h. Immunoprecipitation (IP) and immunoblot (IB) analyses were
done using cell lysates and antibodies speciﬁc for each molecule as described in
Section 2. Data are expressed as the mean ± S.E. (n = 3).
3658 T. Wang et al. / FEBS Letters 583 (2009) 3655–3659transmembrane signaling in response to extracellular stimuli such
as hormones and growth factors [19]. Among PLC family members,
PLCc forms a complex with EGFR and is phosphorylated on tyro-
sine residues. The activated PLCc hydrolyzes phosphatidylinositol
4,5-bisphosphate to generate inositol 1,4,5-triphosphate and diac-
ylglycerol, which leads to PKC phosphorylation [20]. Downregula-
T. Wang et al. / FEBS Letters 583 (2009) 3655–3659 3659tion of EGFR reduced PLCc1 phosphorylation stimulated by evodi-
amine in 3T3-L1 preadipocytes (Fig. 4C). We found reduced levels
of PKCa/b and ERK phosphorylation in cells transfected with EGFR
siRNA, which were similar to the data obtained from experiments
using an EGFR inhibitor. As expected, non-coding RNA had no ef-
fects on the phosphprylation of PLCc1, PKCa/b, and ERK in evodi-
amine-stimulated cells. These results support the idea that
evodiamine stimulates EGFR phosphorylation and transduces a sig-
nal to PLCc1, which activates the PKCa and MEK/ERK signaling
pathways in the early step of preadipocyte differentiation. Sus-
tained ERK activation would then inhibit adipogenesis as reported
[9,21].
We revealed that EGFR (but not TRPV1 nor TRPV4) is a novel
target of evodiamine in preadipocytes, although evodiamine is
known to be an agonist for TRPV1 in the isolated atria and bron-
chus of guinea pigs [4,5]. We also clariﬁed the mechanism that
evodiamine inhibits adipogenesis via activating the EGFR–PKCa–
ERK signaling pathway. Evodiamine may offer a useful strategy
for obesity treatment because adipogenesis regulation appears to
be important for the expansion of adipose tissues.
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